Allergology International最新文献

{"title":"Allergen immunotherapy in asthma","authors":"","doi":"10.1016/j.alit.2024.05.005","DOIUrl":"10.1016/j.alit.2024.05.005","url":null,"abstract":"<div><p>Allergen immunotherapy (AIT), including SCIT and SLIT, is a treatment that involves the administration of allergens to which patients with allergic diseases have been sensitized. HDM-SCIT for asthma is indicated in cases of HDM-sensitized allergic asthma with normal lung function. HDM-SCIT improves asthma symptoms and AHR, and decreases the medication dose. Importantly, AIT can improve other allergic diseases complicated by asthma, such as allergic rhinitis, which can also contribute to the improvement of asthma symptoms. Several studies have suggested that HDM-SLIT also attenuates the risk of asthma exacerbations, and improves lung function in asthma cases with allergic rhinitis. Furthermore, AIT can modify the natural course of allergic diseases, including asthma. For example, the effects of AIT are maintained for at least several years after treatment discontinuation. AIT can prevent the onset of asthma when introduced in allergic rhinitis, and can also inhibit or reduce new allergen sensitizations. Recent data have suggested that AIT may suppress non-targeted allergen-induced immune responses in addition to targeted allergen-induced responses, and suppress infections of the lower respiratory tract by enhancing IFN responses.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 487-493"},"PeriodicalIF":6.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S132389302400056X/pdfft?md5=111d276e9163c087baa89fee53a87a63&pid=1-s2.0-S132389302400056X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of very-low-dose oral food challenge in children with severe hen egg allergy: A retrospective, single-center case series","authors":"","doi":"10.1016/j.alit.2024.05.006","DOIUrl":"10.1016/j.alit.2024.05.006","url":null,"abstract":"<div><h3>Background</h3><p>To avoid complete elimination of hen eggs (HE) from diet, we introduced a very-low-dose (VLD) oral food challenge (OFC) in patients with severe HE allergy in 2019. Herein, we investigated the efficacy of VLD HE OFC for achieving the full dose OFC.</p></div><div><h3>Methods</h3><p>Patients with an overt allergic reaction to LD (1/32 HE [≤100 mg]) or less, egg white (EW) protein within 6 months were included. In the VLD group, patients not achieving full-dose OFC (1/2 HE: 1600 mg EW protein) within 2 years were excluded. We retrospectively compared the rate of passing a full-dose OFC between patients who underwent a LD OFC before 2019 (LD group) and those who underwent a VLD OFC (1/100 HE: 32 mg EW protein) after 2019 (VLD group). The period for passing the full-dose OFC was evaluated using Kaplan–Meier survival analysis.</p></div><div><h3>Results</h3><p>We enrolled 411 and 111 patients in the LD and VLD groups, respectively. The median age at OFC initiation was 2.2 [1.5–3.6] and 2.1 [1.4–3.2] years in the LD and VLD groups, respectively. EW- and ovomucoid-specific IgE levels were 38.3 (12.5–72.9) and 21.0 (8.3–46.2) kU_A/L in the LD group and 49.8 [18.8–83.9] and 32.1 [15.6–67.8] kU_A/L in the VLD group, respectively. Over 4 years, the LD and VLD groups passed the full-dose OFC at rates of 70 and 95%, respectively, with significant differences (log-rank test, <em>P</em> &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>VLD HE OFC may contribute to passing a full-dose OFC in patients with severe HE allergies.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 543-549"},"PeriodicalIF":6.2,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000728/pdfft?md5=044f126a4253d56df28e62e8e2dbc291&pid=1-s2.0-S1323893024000728-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucus plugs in severe asthma and related airway diseases","authors":"Koichiro Asano Associate Editor, Allergology International","doi":"10.1016/j.alit.2024.06.001","DOIUrl":"https://doi.org/10.1016/j.alit.2024.06.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 3","pages":"Pages 349-350"},"PeriodicalIF":6.8,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000571/pdfft?md5=08e72cc8d310f7e5f55ba934956b9b73&pid=1-s2.0-S1323893024000571-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141429791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin testing and challenge in patients with immediate hypersensitivity reactions to gadolinium-based contrast agents identify safe future options","authors":"","doi":"10.1016/j.alit.2024.05.002","DOIUrl":"10.1016/j.alit.2024.05.002","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 610-614"},"PeriodicalIF":6.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000534/pdfft?md5=c2120844f5b29b287c8202d59851d76a&pid=1-s2.0-S1323893024000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141181155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of sequential fecal-marker examination for evaluating gastrointestinal inflammation in solid food protein-induced enterocolitis syndrome","authors":"","doi":"10.1016/j.alit.2024.05.001","DOIUrl":"10.1016/j.alit.2024.05.001","url":null,"abstract":"<div><h3>Background</h3><p>Food protein-induced enterocolitis syndrome caused by solid foods (Solid-FPIES) is a non-immunoglobulin E-mediated allergic disease characterized by delayed gastrointestinal symptoms. An oral food challenge (OFC) test, although necessary, can be inconclusive in cases with mild symptoms. Moreover, limited diagnostic marker availability highlights the need for novel surrogate markers. We aimed to examine the efficacy of fecal hemoglobin (FHb), lactoferrin (FLf), and calprotectin (FCp) over time in evaluating gastrointestinal inflammation degree in Solid-FPIES.</p></div><div><h3>Methods</h3><p>This observational study included 40 patients and 42 episodes at Juntendo University Hospital and affiliated hospitals between October 2020 and March 2024 categorized into FPIES (12 patients with 11 egg yolk, 1 fish, and 1 soybean episodes), control (14 patients with 15 episodes), and remission (14 patients). Fecal tests were performed for 7 days following antigen exposure. The ratios of each value were divided by the baseline value and analyzed over time course.</p></div><div><h3>Results</h3><p>The FPIES group had significantly higher peak ratios of all fecal markers than the control group (p &lt; 0.01). The median FHb, FLf, and FCp ratios were 3.25, 9.09, and 9.79 in the FPIES group and 1.08, 1.29, and 1.49 in the control group, respectively. In the remission group, several patients had fluctuating fecal markers despite negative OFC, and one patient was diagnosed with FPIES by OFC with increased load. Receiver operating characteristic curve analyses revealed high diagnostic performance for each fecal marker in FPIES.</p></div><div><h3>Conclusions</h3><p>Sequential fecal marker examination proved valuable in diagnosing Solid-FPIES and evaluating the degree of gastrointestinal inflammation.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 556-562"},"PeriodicalIF":6.2,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000522/pdfft?md5=3b2895af9d89aa1f3f7167766395b810&pid=1-s2.0-S1323893024000522-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study","authors":"","doi":"10.1016/j.alit.2024.04.006","DOIUrl":"10.1016/j.alit.2024.04.006","url":null,"abstract":"<div><h3>Background</h3><p>We investigated the efficacy and safety of dupilumab in Japanese patients aged ≥6 months to &lt;18 years old with moderate-to-severe atopic dermatitis not adequately controlled with existing therapies.</p></div><div><h3>Methods</h3><p>In this randomized, double-blind, phase 3 study, patients received dupilumab (n = 30) or placebo (n = 32) with concomitant topical corticosteroids for 16 weeks, then all patients received dupilumab from 16 to 52 weeks. The primary endpoint was the proportion of patients with ≥75% improvement in Eczema Area and Severity Index (EASI) score from baseline (EASI-75) to Week 16. Key secondary endpoints included changes in EASI score, proportion of patients with investigator global assessment (IGA) scores of 0/1, and changes in worst daily itch numerical rating scale (NRS) scores (evaluated in patients aged ≥6 to &lt;12 years [n = 35]).</p></div><div><h3>Results</h3><p>At Week 16, more patients achieved EASI-75 with dupilumab than placebo (43.3% vs 18.8%; P = 0.0304), and the least squares mean (LSM) difference in percent change in EASI scores at Week 16 of dupilumab vs placebo was –39.4% (P = 0.0003). However, no significant difference in the proportion of patients achieving IGA scores of 0/1 at Week 16 with dupilumab versus placebo were seen (10.0% vs 9.4%; P = 0.8476). The percent change in worst daily itch NRS scores at Week 16 was higher with dupilumab (LSM difference: –33.3%; nominal P = 0.0117). Dupilumab was well tolerated; no new safety signals were identified.</p></div><div><h3>Conclusions</h3><p>Dupilumab showed consistent efficacy and was well tolerated in Japanese patients aged ≥6 months to &lt;18 years with moderate-to-severe atopic dermatitis previously insufficiently controlled with existing therapies.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 532-542"},"PeriodicalIF":6.2,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000509/pdfft?md5=e2e8a5fa01e194145fb4bc9426f73c8c&pid=1-s2.0-S1323893024000509-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140910968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of food protein-induced enterocolitis syndrome with metabolic acidosis: A case–control study","authors":"","doi":"10.1016/j.alit.2024.04.007","DOIUrl":"10.1016/j.alit.2024.04.007","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 603-606"},"PeriodicalIF":6.2,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000510/pdfft?md5=5995171773065a90c132720803cd400b&pid=1-s2.0-S1323893024000510-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140903790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the diagnostic performance of tryptase and histamine for perioperative anaphylaxis: A multicenter prospective study","authors":"","doi":"10.1016/j.alit.2024.04.005","DOIUrl":"10.1016/j.alit.2024.04.005","url":null,"abstract":"<div><h3>Background</h3><p>Diagnosing perioperative anaphylaxis (POA) is often challenging. Although a guideline recommends measuring tryptase rather than histamine, there is little evidence for this. We aimed to examine the diagnostic performance and appropriate timing of tryptase and histamine measurements for diagnosing anaphylaxis, and the association between Hypersensitivity Clinical Scoring Scheme (HCSS) scores and elevated biomarkers.</p></div><div><h3>Methods</h3><p>We measured tryptase and histamine levels thrice: 30 min, 2 h, and at least 24 h after an anaphylactic event for patients with suspected anaphylaxis, and at the induction of general anesthesia and 30 min and 2 h after the start of surgery for control patients without a reaction. Absolute values and the magnitude and rate of change from baseline were evaluated. We determined the thresholds of tryptase and histamine levels with the best diagnostic performance and compared their performance.</p></div><div><h3>Results</h3><p>Forty-five patients with perioperative anaphylaxis were included in this study. The control group included 30 patients with uneventful general anesthesia and 12 patients with a suspected but unconfirmed diagnosis of perioperative anaphylaxis. Comparison at the same measurement timings showed that tryptase generally had better diagnostic performance than histamine. Both showed better diagnostic performance when assessed using multiple measurements rather than a single measurement. The best diagnostic performance was seen with the percentage change in the higher tryptase value, whether measured at 30 min or 2 h after anaphylaxis onset, as compared to baseline. However, neither tryptase nor histamine levels correlated with HCSS scores.</p></div><div><h3>Conclusions</h3><p>Overall, tryptase showed better diagnostic performance than histamine. When multiple tryptase measurements are possible, parameters calculated using two acute phase measurements and the baseline level have better diagnostic performance.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 573-579"},"PeriodicalIF":6.2,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000492/pdfft?md5=206748e87a17ddea853ca158b792c5aa&pid=1-s2.0-S1323893024000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging cell and molecular targets for treating mucus hypersecretion in asthma","authors":"Ana M. Jaramillo ,&nbsp;Eszter K. Vladar ,&nbsp;Fernando Holguin ,&nbsp;Burton F. Dickey ,&nbsp;Christopher M. Evans","doi":"10.1016/j.alit.2024.04.002","DOIUrl":"10.1016/j.alit.2024.04.002","url":null,"abstract":"<div><p>Mucus provides a protective barrier that is crucial for host defense in the lungs. However, excessive or abnormal mucus can have pathophysiological consequences in many pulmonary diseases, including asthma. Patients with asthma are treated with agents that relax airway smooth muscle and reduce airway inflammation, but responses are often inadequate. In part, this is due to the inability of existing therapeutic agents to directly target mucus. Accordingly, there is a critical need to better understand how mucus hypersecretion and airway plugging are affected by the epithelial cells that synthesize, secrete, and transport mucus components. This review highlights recent advances in the biology of mucin glycoproteins with a specific focus on MUC5AC and MUC5B, the chief macromolecular components of airway mucus. An improved mechanistic understanding of key steps in mucin production and secretion will help reveal novel potential therapeutic strategies.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 3","pages":"Pages 375-381"},"PeriodicalIF":6.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000467/pdfft?md5=5edd5dd24f4e777a3916e07466c0f58b&pid=1-s2.0-S1323893024000467-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of basal cells in nasal polyp epithelium in the pathophysiology of eosinophilic chronic rhinosinusitis (eCRS)","authors":"","doi":"10.1016/j.alit.2024.04.001","DOIUrl":"10.1016/j.alit.2024.04.001","url":null,"abstract":"<div><h3>Background</h3><p>Basal cell hyperplasia is commonly observed in nasal polyp epithelium of eosinophilic chronic rhinosinusitis (eCRS). We examined the function and mechanisms of basal cell hyperplasia in the pathophysiology of eCRS.</p></div><div><h3>Methods</h3><p>We found that normal human bronchial epithelial (NHBE) cells obtained basal cell characteristics when cultured with PneumaCult™-Ex Plus Medium. Most of the cells passaged three times expressed basal cell surface markers CD49f and CD271 by flow cytometry, and basal cell nuclear marker p63 by immunohistochemical staining. We named these NHBE cells with basal cell characteristics cultured Basal-like cells (cBC), and NHBE cells cultured with BEGM™ cultured Epithelial cells (cEC). The characteristics of cBC and cEC were examined and compared by RNA sequencing, RT-PCR, ELISA, and cell proliferation studies.</p></div><div><h3>Results</h3><p>RNA sequencing revealed that cBC showed higher gene expression of thymic stromal lymphopoietin (TSLP), IL-8, TLR3, and TLR4, and lower expression of PAR-2 compared with cEC. The mRNA expression of TSLP, IL-8, TLR3, and TLR4 was significantly increased in cBC, and that of PAR-2 was significantly increased in cEC by RT-PCR. Poly(I:C)-induced TSLP production and LPS-induced IL-8 production were significantly increased in cBC. IL-4 and IL-13 stimulated the proliferation of cBC. Finally, the frequency of p63-positive basal cells was increased in nasal polyp epithelium of eCRS, and Ki67-positive proliferating cells were increased in p63-positive basal cells.</p></div><div><h3>Conclusions</h3><p>Type 2 cytokines IL-4 and IL-13 induce basal cell hyperplasia, and basal cells exacerbate type 2 inflammation by producing TSLP in nasal polyp of eCRS.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 563-572"},"PeriodicalIF":6.2,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000455/pdfft?md5=8e3034f4fb4da4bb9b4e946528d8fe35&pid=1-s2.0-S1323893024000455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}